Trial · NCT04711603
Adverse events376
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 376
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Double Blind Period: MR13A9 0.5 μg/kg Group | 4 | 89 | 4 |
| other | Constipation | Gastrointestinal disorders | Double Blind Period: Placebo Group | 1 | 89 | 1 |
| other | Constipation | Gastrointestinal disorders | Entire Study: MR-MR Group | 12 | 85 | 13 |
| other | Constipation | Gastrointestinal disorders | Entire Study: P-MR Group | 8 | 83 | 11 |
| other | Diarrhoea | Gastrointestinal disorders | Double Blind Period: MR13A9 0.5 μg/kg Group | 2 | 89 | 2 |
| other | Diarrhoea | Gastrointestinal disorders | Double Blind Period: Placebo Group | 3 | 89 | 4 |
| other | Diarrhoea | Gastrointestinal disorders | Entire Study: MR-MR Group | 11 | 85 | 18 |
| other | Diarrhoea | Gastrointestinal disorders | Entire Study: P-MR Group | 18 | 83 | 26 |
| other | Haemorrhoids | Gastrointestinal disorders | Double Blind Period: MR13A9 0.5 μg/kg Group | 0 | 89 | 0 |
| other | Haemorrhoids | Gastrointestinal disorders | Double Blind Period: Placebo Group | 0 | 89 | 0 |
| other | Haemorrhoids | Gastrointestinal disorders | Entire Study: MR-MR Group | 1 | 85 | 1 |
| other | Haemorrhoids | Gastrointestinal disorders | Entire Study: P-MR Group | 5 | 83 | 6 |
| other | Nausea | Gastrointestinal disorders | Double Blind Period: MR13A9 0.5 μg/kg Group | 2 | 89 | 2 |
| other | Nausea | Gastrointestinal disorders | Double Blind Period: Placebo Group | 1 | 89 | 1 |
| other | Nausea | Gastrointestinal disorders | Entire Study: MR-MR Group | 7 | 85 | 16 |
| other | Nausea | Gastrointestinal disorders | Entire Study: P-MR Group | 5 | 83 | 6 |
| other | Vomiting | Gastrointestinal disorders | Double Blind Period: MR13A9 0.5 μg/kg Group | 3 | 89 | 3 |
| other | Vomiting | Gastrointestinal disorders | Double Blind Period: Placebo Group | 0 | 89 | 0 |
| other | Vomiting | Gastrointestinal disorders | Entire Study: MR-MR Group | 8 | 85 | 8 |
| other | Vomiting | Gastrointestinal disorders | Entire Study: P-MR Group | 3 | 83 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04711603/events